Does anemia correction by rHuEPO improve uremic cardiopathy?
The correction of renal anemia by recombinant human erythropoietin (rHuEPO) makes it possible to assess the effect of anemia on uremic cardiopathy (UC). So far, conflicting results have been reported. We studied 10 hemodialyzed patients aged (51 +/- 18 years, dialytic age 47 +/- 18 months) before and after rHuEPO treatment. All patients underwent an echocardiogram before, and six months after stable hematocrit (31 +/- 2) was obtained. The results show a reduction in LVDD. No improvement in ejection fraction and in ventricular hypertrophy was observed, probably owing to an increase in blood pressure. Finally, there is a possibility that the myocardium of hemodialyzed patients undergoes anatomical changes which may not improve, even after anemia correction.
Carletti
P
P
Divisione di Nefrologia e Dialisi, Ospedale Regionale-Torrette, Ancona, Italy.
Bibiano
L
L
Boggi
R
R
Taruscia
D
D
Mioli
V
V
D000328:Adult; D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006331:Heart Diseases / Q000209:etiology / Q000473:pathology / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D014511:Uremia / Q000150:complications*; D016276:Ventricular Function
D011994:Recombinant Proteins; D004921:Erythropoietin